0000950170-23-068283.txt : 20231205 0000950170-23-068283.hdr.sgml : 20231205 20231205172322 ACCESSION NUMBER: 0000950170-23-068283 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231201 FILED AS OF DATE: 20231205 DATE AS OF CHANGE: 20231205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Simonian Nancy A CENTRAL INDEX KEY: 0001359574 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37813 FILM NUMBER: 231467667 MAIL ADDRESS: STREET 1: C/O SYROS PHARMACEUTICALS, INC. STREET 2: 620 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Syros Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001556263 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 453772460 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 CAMBRIDGE PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: 617-744-1340 MAIL ADDRESS: STREET 1: 35 CAMBRIDGE PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 FORMER COMPANY: FORMER CONFORMED NAME: LS22, Inc. DATE OF NAME CHANGE: 20120815 4 1 ownership.xml 4 X0508 4 2023-12-01 0001556263 Syros Pharmaceuticals, Inc. SYRS 0001359574 Simonian Nancy A C/O SYROS PHARMACEUTICALS, INC. 35 CAMBRIDGEPARK DRIVE CAMBRIDGE MA 02140 true false false false false Stock Option (right to buy) 121.70 2023-12-01 4 D false 7500 D 2026-09-15 Common Stock 7500 0 D Stock Option (right to buy) 109 2023-12-01 4 D false 17499 D 2027-02-09 Common Stock 17499 0 D Stock Option (right to buy) 100.90 2023-12-01 4 D false 28001 D 2028-02-15 Common Stock 28001 0 D Stock Option (right to buy) 75.40 2023-12-01 4 D false 29399 D 2030-02-12 Common Stock 29399 0 D Stock Option (right to buy) 114.10 2023-12-01 4 D false 30399 D 2031-02-16 Common Stock 30399 0 D Fully vested. The option was canceled by mutual agreement of the reporting person and the issuer pursuant to the terms of the Retirement and Transition Agreement, dated September 28, 2023, by and between the reporting person and the issuer, a copy of which was filed on November 14, 2023 as Exhibit 10.1 to the issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023. This option vested as to 25% of the shares on February 28, 2021, with the remainder vesting in equal monthly installments thereafter through February 28, 2024. This option vested as to 25% of the shares on February 28, 2022, with the remainder vesting in equal monthly installments thereafter through February 28, 2025. Amounts reported in this Form 4 reflect the 1-for-10 reverse stock split effected by the issuer on September 16, 2022. /s/ Todd Rosenthal, as attorney-in-fact 2023-12-05